Previous 10 | Next 10 |
2023-08-09 17:49:15 ET Interpace Biosciences press release ( OTCQX:IDXG ): Q2 GAAP EPS of $0.09. Revenue of $11.03M (+49.1% Y/Y). For further details see: Interpace Biosciences GAAP EPS of $0.09, revenue of $11.03M
PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update. Second quarter Ne...
Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history 1 st Half Revenue $20.9 million; 36.1% improvement over 1 st Half 2022 Q2 Test volume up 15.2% year-over-year to record l...
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testi...
2023-05-12 16:28:43 ET Interpace Biosciences press release ( OTCQX:IDXG ): Q1 GAAP EPS of $0.10. Revenue of $9.8M (-5.6% Y/Y). For further details see: Interpace Biosciences GAAP EPS of $0.10, revenue of $9.8M
PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net ...
2023-03-27 17:18:33 ET Interpace Biosciences press release ( OTCQX:IDXG ): Q4 GAAP EPS of -$0.33. Revenue of $8.33M (-8.6% Y/Y). For further details see: Interpace Biosciences GAAP EPS of -$0.33, revenue of $8.33M
PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2022 and provided a business and financial update. ...
Interpace Biosciences press release ( OTCQX:IDXG ): Q3 GAAP EPS of $3.35. Revenue of $8.2M Gross Profit percentage was 58% compared to 55% for the prior year quarter, an improvement year over year. Loss from Continuing Operations was approximately$(1.3) million in both...
Q3 Revenue of $ 8.2 million up 2 % versus Prior Year Q3 Adjusted EBITDA Positive Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...